Compared with patients in cohort-2019, those in cohort-2021 had a larger body weight, larger BMI, higher SBP, higher DBP, faster HR, lower eGFR, lower LDL, lower TG, a smaller proportion of patients with hypertension, and a larger proportion of glucagon-like peptide-1 receptor agonist (GLP-1 RA) use. Here, GLP1R is linked to hypertensive disorder.